Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

Why do we need a policy change?

The legislation in place today for regulating in silico products actually predates the existence of these technologies. In order for the in silco market to grow and for research in this field to be encouraged, a policy framework for in silico medicine needs to be developed. Just as the internet has created an urgent need to reform how we think about issues such as data security and IPR, in silico medicine requires we reevaluate our existing health policy structures.

Even the most advanced and predictive model has little value to industry if it cannot be submitted as evidence of the effectiveness or safety of their product:

  • Manufacturers of medical devices who use in silico technologies must be provided with a framework for submitting this data to notified bodies, health authorities and evaluators of health technologies.
  • Similarly for pharmaceuticals, a framework for admissibility of in silico clinical trial data needs to be developed so that we can move from exploratory clinical trials in humans, to a scenario where we seek to confirm what we know from in silico methods.

Incentives in policy need to be provided for industries that pioneer this research which has the potentially to drastically decrease overall research costs and greatly improve patient safety. Providing a system for assessing modelling and simulation data that supplement efficacy or safety data is required to bring healthcare into the digital era.

“If healthcare is to move into the digital era, we need new policies that will enable this transition”

NEWS

News In Silico Medicine: A New Scientific Discipline Emerges in Greece

In Silico Medicine: A New Scientific Discipline Emerges in Greece

On December 21, 2024, Research Professor Georgios S. Stamatakos, a great pioneer of in silico oncology, delivered a lecture in Sparta, Greece, exploring the emergence, evolution, and clinical potential of in silico medicine.

News Introducing the plain language in silico medicine glossary

Introducing the plain language in silico medicine glossary

As in silico medicine continues to advance, new concepts and terms emerge rapidly—often before widespread consensus is established. To make this transformative field more accessible to all the stakeholders including the patients, we are pleased to present the “Plain language in silico medicine glossary”, now published on Zenodo.

News Happy New Year, 2025, the Millennium Year

Happy New Year, 2025, the Millennium Year

Dear Avicenna Alliance members, As we welcome the new year, we hope you had a joyful holiday season filled with moments of relaxation and happiness with your loved ones.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2025 Avicenna Alliance | powered by We Berry